The proceeds will be used for further business expansion.
Pulsemed (Chinese: 脉搏医疗科技) recently announced its completion of a Series C financing round. The round was co-invested by For Future Equity Investment (Chineses: 为来资本) and Yuecai Biomedicine Fund (Chinese: 粤财生物医药基金). StartPointAdvisors(Chineses: 行远致同) acted as its exclusive financial advisor.
Pulsemed, founded in 2014, is a MedTech enterprise specializing in cardiovascular medical equipment R&D and manufacturing.
Its competitors include Newmed (Chinese: 纽脉医疗), Lepu Medical(Chinese: 乐普医疗) and MicroPort Endovascular MedTech(Chineses: 心脉医疗).